Hemostemix appoints Hsiang as business consultant

Executive Summary

• Hemostemix Inc. has appointed Dr. York Hsiang, a renowned vascular surgeon and former principal investigator, as a business consultant.
• The appointment is part of a strategic initiative to advance First Nations-led healthcare partnerships and establish joint ventures for healthcare centers on sovereign territories.
• Dr. Hsiang’s role involves advising on joint ventures, clinical staffing models, commercialization pathways, and the ethical scale-up of the company’s ACP-01 therapy.

Key Details

• Appointment: Dr. York Hsiang appointed as Business Consultant.
• Dr. Hsiang’s Background:
  • Renowned vascular surgeon and Professor Emeritus of Surgery at the University of British Columbia (UBC) Faculty of Medicine.
  • Former principal investigator of Hemostemix’s Phase II clinical trial for ACP-01.
  • Career spanning over three decades in vascular surgery, endovascular innovation, and health-system governance.
  • Former Division Head of Vascular Surgery at UBC and Managing Director of the Physician Staff Association at Vancouver Hospital.
• Strategic Mandate:
  • Advise on joint ventures with First Nations governments to establish healthcare and treatment centers on sovereign territories.
  • Develop clinical staffing models and physician engagement standards for ACP-01 delivery.
  • Advise on strategic commercialization pathways in Canada, Florida (under SB 1768), and The Bahamas.
  • Focus on ethical scale-up for patients with circulatory insufficiency who have exhausted conventional options.
• Partnership Principles:
  • Respect for Indigenous sovereignty and jurisdiction over healthcare.
  • Long-term economic stewardship and intergenerational value creation.
  • Capacity-building, training, and local employment within First Nations communities.
  • Physician-led, ethics-driven delivery of care.
  • Establishment of destination health care centers blending clinical excellence with traditional cultural healing.
• Product Context (ACP-01):
  • Autologous blood-based stem cell therapy.
  • Phase II trial results published in the Journal of Biomedical Research & Environmental Science.
  • Reported outcomes for Chronic Limb Threatening Ischemia (CLTI): 0% mortality, cessation of pain, and wound healing in 83% of patients followed for up to 4.5 years.

Notable Quotes

• Thomas Smeenk, President and CEO: "Since 2006, the first question I have asked every principal investigator I meet is simple: 'Doctor, does ACP-01 work?' Without exception, the answer has been an enthusiastic 'Yes.' When Dr. Hsiang answered that question, he added something I have never forgotten: ' ... in 30 years of medical practice I have not witnessed a therapy as effective as ACP-01,'"
• Dr. York Hsiang: "For peripheral arterial disease patients, there are beneficial treatments to minimize pain and preserve function. However, for no option critical threatening limb ischemia (CTLI) patients, a timely amputation was the only procedure offered. ACP-01 is a dramatic game changer for suitable patients with no option CTLI. In 30 years of practice I have not seen a therapy as effective as ACP-01"